Skip Navigation LinksHome > January 28, 2009 - Volume 23 - Issue 3 > Efficacy and safety of etravirine (TMC125) in treatment-expe...
doi: 10.1097/QAD.0b013e32831c5040
Research Letters

Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial

Cohen, Calvin Ja; Berger, Daniel Sb; Blick, Garyc; Grossman, Howard Ad; Jayaweera, Dushyantha Te; Shalit, Peterf; Thompson, Melanieg; Peeters, Monikah; de Béthune, Marie-Pierreh; Voorspoels, Ellenh; Mack, Rebeccai; Woodfall, Brianh

Collapse Box


Forty-eight-week results from a randomized, multicentre, part-blinded, phase IIb clinical trial assessing the efficacy and safety of 400 and 800 mg etravirine twice daily (phase IIb formulation) and optimized background regimen versus standard-of-care regimen are presented. Both etravirine doses demonstrated sustained virological suppression at 48 weeks and a favourable tolerability profile. Etravirine demonstrated higher efficacy than control, irrespective of the number of detectable nonnucleoside reverse transcriptase inhibitor-resistance-associated mutations at baseline or active background antiretrovirals.

© 2009 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics